On Friday, September 9, 2016, Advaxis unveiled their new manufacturing facility and laboratory during a ribbon-cutting ceremony at their Princeton, NJ headquarters. The event included remarks from New Jersey Governor Christopher J. Christie and BioNJ president and CEO Debbie Hart, before close to 200 people.
Advaxis built out the 30,000-square-foot expansion at its College Road East headquarters to include a clean-room manufacturing and laboratory facility to develop and manufacture clinical-grade products to support Advaxis’ clinical trials and future commercialization of its immuno-oncology therapeutics.
Advaxis is currently conducting several clinical trials evaluating is proprietary Lm Technology™ using bioengineered live attenuated Listeria monocytogenes bacteria to activate the immune system to attack cancer cells, including the Phase 3 AIM2CERV study in patients with high-risk, locally advanced cervical cancer.
In addition, the facility will be used to manufacture ADXS-NEO as part of their My Immunotherapy Neo-Epitopes or MINE™ program, which will enter phase 1 trials in 2017 through a global collaboration agreement with Amgen.